Cladribine (Mavenclad) for multiple sclerosis
- PMID: 31381552
Cladribine (Mavenclad) for multiple sclerosis
Keywords: Aubagio; Avonex; Copaxone; Gilenya; Lemtrada; Mavenclad; Mayzent; Ocrevus; Plegridy; Tecfidera; Tysabri; adverse effects; alemtuzumab; cladribine; dimethyl fumarate; dosage; drug interactions; efficacy; fingolimod; glatiramer acetate; interferon beta; lactation; multiple sclerosis; natalizumab; ocrelizumab; pregnancy; safety; siponimod; teriflunomide.
Similar articles
-
Siponimod (Mayzent)--a new drug for multiple sclerosis.Med Lett Drugs Ther. 2019 May 6;61(1571):70-72. Med Lett Drugs Ther. 2019. PMID: 31169805 No abstract available.
-
Drugs for multiple sclerosis.Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-48. Med Lett Drugs Ther. 2021. PMID: 33976089 Review. No abstract available.
-
Ozanimod (Zeposia) for multiple sclerosis.Med Lett Drugs Ther. 2020 Aug 24;62(1605):132-134. Med Lett Drugs Ther. 2020. PMID: 32970043 Review. No abstract available.
-
Ublituximab (Briumvi) for relapsing multiple sclerosis.Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-38. doi: 10.58347/tml.2023.1671c. Med Lett Drugs Ther. 2023. PMID: 36877282 No abstract available.
-
Ponesimod (Ponvory) for multiple sclerosis.Med Lett Drugs Ther. 2021 Aug 9;63(1630):123-125. Med Lett Drugs Ther. 2021. PMID: 34550110 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical